Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

2.675 -0.385 (-12.58%)
Streaming Delayed Price Updated: 9:37 AM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,751,008
Open 3.050
Bid (Size) 2.670 (700)
Ask (Size) 2.680 (1,800)
Prev. Close 3.060
Today's Range 2.640 - 3.080
52wk Range 0.8621 - 4.460
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
US stock futures mixed, Nasdaq 100 up over 50 points. JPMorgan shares down 3.1% after beating earnings but missing sales estimates. Other stocks also down in pre-market trading. 
Via Benzinga
News headline image
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
From Allogene Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+98.1%
+98.1%
1 Month
+9.6%
+9.6%
3 Month
+60.2%
+60.2%
6 Month
+110.6%
+110.6%
1 Year
+87.1%
+87.1%

More News

Read More
News headline image
These stocks are making the most noise in today's session. ↗
Via Chartmill
News headline image
ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology
Via AB Newswire
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q4 Loss, Highlights Key 2026 Clinical Catalysts ↗
Via Chartmill
News headline image
Allogene Therapeutics Stock Hits 52-Week High - Here's Why ↗
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
Topics Stocks
News headline image
Which stocks are moving before the opening bell on Monday? ↗
Via Chartmill
News headline image
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene (ALLO) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses ↗
Via The Motley Fool
Topics Stocks
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
From Equity Insider
Via GlobeNewswire
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
What a Billionaire Family Office's $16.6 Million Exit From TIC Solutions Signals for Long-Term Investors ↗
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday ↗
Via Benzinga
News headline image
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Unseen Hand: Congressional Leaders Under Fire for Alleged Stock Market Outperformance
Via MarketMinute
Topics Bonds ETFs World Trade

Frequently Asked Questions

Is Allogene Therapeutics, Inc. - Common Stock publicly traded?
Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?
Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?
The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market
What is the current price of Allogene Therapeutics, Inc. - Common Stock?
The current price of Allogene Therapeutics, Inc. - Common Stock is 2.675
When was Allogene Therapeutics, Inc. - Common Stock last traded?
The last trade of Allogene Therapeutics, Inc. - Common Stock was at 04/14/26 09:37 AM ET
What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 380.34M
How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
Allogene Therapeutics, Inc. - Common Stock has 380M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.